Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of faricimab in diabetic macular edema
2020-000402-29Phase 3Completed
- Sponsor
- Roche
- Start
- May 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of faricimab in diabetic macular edema (DME), sponsored by Roche. Primary endpoint: Incidence and severity of ocular adverse events. Started May 2020; status: completed.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2020-000402-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000402-29.